{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:11:37Z","timestamp":1778803897295,"version":"3.51.4"},"reference-count":23,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>With an aging population, multiple myeloma (MM) increasingly affects octogenarians (Octos; age of \u226580 years), yet data on their management and outcomes, particularly if treated outside clinical trials, remain limited. This retrospective study analyzed 652 patients aged \u226570 years, diagnosed with active MM between 2014 and 2023, identified in the Maccabi Healthcare Services medical records. Patient characteristics, treatment, time to next treatment (TTNT), overall survival (OS), and factors influencing outcomes, were compared between Octo and older adults (OL) aged 70 to &amp;lt;80 years. Octo patients (median age, 83 years) had more comorbidities and higher Charlson Comorbidity Index (CCI) scores than OL patients (\u22656; 53% vs 23%), leading to lower rates of anti-MM therapy administration and reduced triplet\/quadruplet regimen use. Over a median follow-up of 25 months, Octo patients had significantly shorter median OS; 25.9 vs 71.3 months, and 33 vs 76.9 months among treated patients only. TTNT was similar (17.8 vs 22.1 months). Multivariate analysis showed that triplet\/quadruplet regimen was associated with improved TTNT (hazard ratio [HR], 0.61; P &amp;lt; .001) and OS (HR, 0.63; P &amp;lt; .001) compared with doublets, whereas higher CCI scores and age of \u226580 years predicted worse OS (HR, 1.5; P = .003; and HR, 2.27; P &amp;lt; .001; respectively). Daratumumab-based therapies enhanced TTNT in both age groups (HR, 0.54; P = .017). In conclusion, higher comorbidities in Octo patients adversely affected their management and survival. However, daratumumab positively influenced outcomes, underscoring the need for tailored approaches to optimize treatment in older patients with MM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015968","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T22:17:16Z","timestamp":1741299436000},"page":"2677-2685","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4337-1108","authenticated-orcid":false,"given":"Dor","family":"Shpitzer","sequence":"first","affiliation":[{"name":"1Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael C.","family":"Cohen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3741-689X","authenticated-orcid":false,"given":"Tamir","family":"Shragai","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ori","family":"Grossberger","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Amsterdam","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-3112","authenticated-orcid":false,"given":"Anat","family":"Reiner-Benaim","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology, Biostatistics and Community Health Sciences, School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"22","key":"2025061008215508400_bib1","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2025061008215508400_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2025061008215508400_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"27","key":"2025061008215508400_bib4","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"2025061008215508400_bib5","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"issue":"24","key":"2025061008215508400_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025061008215508400_bib7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How I treat multiple myeloma in geriatric patients","volume":"143","author":"Facon","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025061008215508400_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2025061008215508400_bib9","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.3390\/cancers14194741","article-title":"Multiple myeloma in patients over 80: a real world retrospective study of first line conservative approach with bortezomib dexamethasone doublet therapy and mini-review of literature","volume":"14","author":"Huynh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2025061008215508400_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2025061008215508400_bib11","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3324\/haematol.2017.173617","article-title":"Treat or palliate: outcomes of very elderly myeloma patients","volume":"103","author":"Panitsas","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2025061008215508400_bib12","doi-asserted-by":"crossref","first-page":"101592","DOI":"10.1016\/j.jgo.2023.101592","article-title":"Risk of cancer-specific death among octogenarians with multiple myeloma: a population-based analysis","volume":"14","author":"Britto","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"2025061008215508400_bib13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"2025061008215508400_bib14","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"2025061008215508400_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025061008215508400_bib16","first-page":"59","article-title":"Osteoporosis in the community: findings from a novel computerized registry in a large health organization in Israel","author":"Goldshtein","year":"2015","journal-title":"J Aging Res Clin Pract"},{"issue":"12","key":"2025061008215508400_bib17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1023\/B:EJEP.0000006635.36802.c8","article-title":"The epidemiology of diabetes in a large Israeli HMO","volume":"18","author":"Chodick","year":"2003","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"2025061008215508400_bib18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijcard.2010.08.002","article-title":"The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization","volume":"152","author":"Shalev","year":"2011","journal-title":"Int J Cardiol"},{"issue":"11","key":"2025061008215508400_bib19","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"3","key":"2025061008215508400_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10428194.2018.1509323","article-title":"Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients","volume":"60","author":"Gavriatopoulou","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025061008215508400_bib21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2025061008215508400_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2012.01784.x","article-title":"Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era","volume":"89","author":"Dimopoulos","year":"2012","journal-title":"Eur J Haematol"},{"issue":"19","key":"2025061008215508400_bib23","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.3390\/cancers16193329","article-title":"The outcome of octogenarian patients with multiple myeloma treated outside clinical studies, focusing on tolerability and efficacy of treatment","volume":"16","author":"Amsterdam","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2677\/2376819\/blooda_adv-2025-015968-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2677\/2376819\/blooda_adv-2025-015968-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:22:09Z","timestamp":1749558129000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/11\/2677\/535916\/Clinical-outcomes-in-older-adults-treated-outside"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015968","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,10]]},"published":{"date-parts":[[2025,5,28]]}}}